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Theranostics is the term used to define targeted therapy 
based on targeted diagnostic tests. This phenomenon has 
been in use in nuclear medicine since the 1940s when 
isotopes of radioactive iodine (I-131 and I-123) were 
introduced to diagnose and treat benign and thyroid 
diseases.[1] Radioiodine labelled metaiodobenzylguanidine, 
an analogue of noradrenaline, is another example 
of theranostics at play in the treatment of metastatic 
neuroblastoma since decades.[2] Radionuclide therapies for 
bone pain palliation (i.e., strontium-89, samarium-153 and 
radium-223) work on the similar principle by targeting the 
osteoblastic metastases documented on the conventional 
bone scintigraphy.[3]
In the 21st century, theranostics is a part of the personalized 
and precision medicine. New radiotracers are available 
for use with hybrid single-photon emission computed 
tomography (SPECT) and positron emission tomography 
(PET) scanners, the latter being the more superior 
modality. PET tracer i.e., Flouride-18 and Gallium-68 
labelled somatostatin analogues have higher affinity than 
the SPECT-based tracers such as indium-111 (In-111) or 
technetium (Tc-99m) octreotide.[4] On the therapeutic 
front high-energy β (beta) emitters such as lutetium-177 
(Lu-177) and yttrium-90 (Y-90) lead the way along with 
radium (Ra 223) an α (alpha) emitter.[5,6]
One area where theranostics is making promising headway 
is the metastatic neuroendocrine tumours (NETs). NETs 
are relatively rare and heterogeneous neoplasms which 
are grouped together due to their distinct features, which 
are hormone production and metabolism, histology and 
expression of somatostatin receptors (SSRs) on the cell 
surface.
Functional imaging of the NETs can be done using 
the metabolic or peptide radiotracers. The metabolic 
radiotracers are modified precursors which are further 
modified by the NET cell. The peptide radiotracers 
bind to specific receptors on tumour cell surface. The 
peptide radiotracers which are internalized after binding 
to the receptors are ‘agonists’ while those which are not 
internalized are the ‘antagonists.’[6,7]
Patients with NETs may present with local tumours and 
with or without regional or distant metastases with liver 
being the most common site. These tumours may remain 
clinically silent until a significant liver tumour burden is 
present. Therapeutic options for NET include surgery, 
somatostatin analogues, interferon, chemotherapy, 
molecularly targeted agents, locoregional therapies and 
peptide receptor radionuclide therapy (PRRT). Basic 
underlying principle remains that the disease with high 
SSR receptor expression documented with somatostatin 
analogue scintigraphy can be treated with similar 
analogues labelled with Lu-177 and Y-90. Individual 
β-emitters elicit variation in energy and path length.
Lu-177 PRRT was supposed to be more suited for smaller 
tumour volumes compared with Y90 which emits more 
energetic particles with longer path length.[7,8] However, 
Kunikowska et al. demonstrated that overall survival 
is significantly higher in patients treated with the 
combination of Y-90/Lu-177 DOTA-TATE compared with 
Y-90 DOTA-TATE alone.[9]
The most significant breakthrough for the role of PRRT 
has been the NETTER-1 Phase III Trial of Lu-177 
DOTA-TATE for midgut NET.[10] Strosberg et al. 
conducted an international multicentre randomized, 
controlled trial across 41 centres in eight countries. 
The trail evaluated the efficacy and safety of Lu-177 
DOTA-TATE (7.4 GBq every 8 weeks × 4 administrations) 
and octreotide LAR (60 mg) in 229 patients with 
advanced, progressive and somatostatin-receptor-positive 
midgut NET. The trial results showed evidence for a 
clinically meaningful and statistically significant increase 
in progression-free survival (65.2% vs. 10.8%) and 
objective radiographic response (18% vs. 3%). Clinically 
significant myelosuppression was noted in <10% of 
patients treated with Lu-177 DOTA-TATE. Trial findings 
suggested a potential survival benefit in treating advanced 
midgut NET with Lu-177 DOTA-TATE.[10,11,12]
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In 2013, the international atomic energy agency along 
with the European Association of Nuclear Medicine 
and the Society of Nuclear Medicine and Molecular 
Imaging (SNMMI) issued a joint practical guidance 
on PRRT.[13] This joint effort was based on review of 
experience and data acquired over 15 years, initiated in 
Europe. Past 2 years have been very favourable for the 
clinical use of NET theranostics given that in 2016 FDA 
approved Ga-68 DOTA-TATE for imaging followed by 
Lu-177 DOTA-TATE for therapy in 2018 following the 
NETTER-1 trial results.
PRRT for NET represents the tip of the iceberg in terms 
of theranostics. Prostate cancer is yet another area of 
significant focus.[14] Promising results for Lu-177 PSMA 
are breaking ground at the 2018 SNMMI meeting in 
Philadelphia as these lines are drafted.[15]
Precision and personalized medicine is the way that 
things are headed. In the process, terminologies are being 
invented and modified to reflect the changes and highlight 
the focus. Theranostics is lately changing to theragnostics 
to highlight the importance of prognosis amidst diagnosis 
and treatment.[16] Let’s see what more future has to offer.
References
1. Sawin CT, Becker DV. Radioiodine and the treatment of 
hyperthyroidism: The early history. Thyroid 1997;7:163-76.
2. Sharp SE, Trout AT, Weiss BD, et al. MIBG in neuroblastoma 
diagnostic imaging and therapy. Radiographics 
2016;36:258-78.
3. Van den Wyngaert T, Strobel K, Kampen WU, et al. The 
EANM practice guidelines for bone scintigraphy. Eur J Nucl 
Med Mol Imaging 2016;43:1723-38.
4. Kunikowska J, Lewington V, Krolicki L. Optimizing 
somatostatin receptor imaging in patients with 
neuroendocrine tumors: The impact of 99mTc-HYNICTOC 
SPECT/SPECT/CT versus 68Ga-DOTATATE PET/CT upon 
clinical management. Clin Nucl Med 2017;42:905-11.
5. Dorff TB, Agarwal N. Bone-targeted therapies to reduce 
skeletal morbidity in prostate cancer. Asian J Androl 
2018;20:215-20.
6. Lee DY, Li KC. Molecular theranostics: A primer for the 
imaging professional. AJR Am J Roentgenol 2011;197:318-24.
7. Oberg K. Molecular imaging radiotherapy: Theranostics for 
personalized patient management of neuroendocrine tumors 
(NETs). Theranostics 2012;2:448-58.
8. Kulkarni HR, Singh A, Baum RP. Advances in the 
diagnosis of neuroendocrine neoplasms. Semin Nucl Med 
2016;46:395-404.
9. Kunikowska J, Pawlak D, Bąk MI, et al. Long-term results 
and tolerability of tandem peptide receptor radionuclide 
therapy with90Y/177 Lu-DOTATATE in neuroendocrine 
tumors with respect to the primary location: A 10-year study. 
Ann Nucl Med 2017;31:347-56.
10. Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of177 
Lu-dotatate for midgut neuroendocrine tumors. N Engl J 
Med 2017;376:125-35.
11. Strosberg J, Wolin E, Chasen B, et al. Health-related quality 
of life in patients with progressive midgut neuroendocrine 
tumors treated with177 Lu-dotatate in the phase III 
NETTER-1 trial. J Clin Oncol 2018;36:2578-84.
12. Mittra ES. Neuroendocrine tumor therapy:177 Lu-
DOTATATE. AJR Am J Roentgenol 2018;211:278-85.
13. Bodei L, Mueller-Brand J, Baum RP, et al. The joint IAEA, 
EANM, and SNMMI practical guidance on peptide receptor 
radionuclide therapy (PRRNT) in neuroendocrine tumours. 
Eur J Nucl Med Mol Imaging 2013;40:800-16.
14. Virgolini I, Decristoforo C, Haug A, et al. Current status of 
theranostics in prostate cancer. Eur J Nucl Med Mol Imaging 
2018;45:471-95.
15. Hofman M, Violet J, Sandhu S, et al. High activity, pain 
reduction and low toxicity with lutetium-177 PSMA617 
theranostics in metastatic castrate-resistant prostate cancer 
(mCRPC): Results of a phase II prospective trial. J Nucl 
Med 2018;59 Supplement 1:531.
16. Keek SA, Leijenaar RT, Jochems A, et al. A review on 
radiomics and the future of theranostics for patient selection 
in precision medicine. Br J Radiol 2018;91:20170926.
M. Numair Younis1, Humayun Bashir2
1Department of Nuclear Medicine, Institute of Nuclear 
Medicine and Oncology, Lahore, Pakistan, 2Department 
of Nuclear Medicine, Shaukat Khanum Memorial 
Cancer Hospital and Research Centre, Lahore, Pakistan
Received: 15 June 2018 / Accepted: 28 Jun 2018
